Ask AI
ProCE Banner Activity

TROPION-Breast02: Dato-DXd vs Investigator’s Choice of CT as 1L Treatment in Patients With TNBC Who Are Not Candidates for Immunotherapy

Conference Coverage
Slideset

The phase III TROPION-Breast02 trial demonstrated improvement in the coprimary endpoints of PFS and OS with first-line Dato-DXd vs investigator’s choice of chemotherapy in patients with locally recurrent or metastatic TNBC not eligible for immunotherapy.

Released: October 24, 2025

Share

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by educational grants from AstraZeneca, Daiichi Sankyo, Inc., Gilead Sciences, Inc., Incyte, and Lilly.

AstraZeneca

Daiichi Sankyo, Inc.

Gilead Sciences, Inc.

Incyte

Lilly